SEC Form 4 · accession 0001250853-18-000029
Kindred Biosciences, Inc. · KIN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Denise Bevers
Officer — Chief Financial Officer
Period of report
Jan 22, 2018
Accepted (ET)
Jan 24, 2018 · 8:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001561743
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF4 | Jan 23, 2018 | F | 11,370 | $9.15 | D | 88,630 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $8.75 | Jan 22, 2018 | A | 100,000 | A | — | Jan 22, 2028 | Common Stock | 100,000 | 100,000 | D |
| Restricted Stock UnitsF2,F3 | — | Jan 22, 2018 | A | 110,000 | A | — | — | Common Stock | 110,000 | 110,000 | D |
Explanation of responses
- F1The option will vest as to 25% after one year following the date of grant, and the remainder will vest in equal monthly installments over the following three years.
- F2Each restricted stock unit represents a contingent right to receive one share of Common Stock.
- F3The option will vest as to 25% annually following the date of grant.
- F4These shares are being surrendered to satisfy a tax withholding obligation of the reporting person.